1. WHO Expert Advisory Committee on Developing Global Standards for Governance and Oversight of Human Genome Editing. Human Genome Editing: A Framework for Governance (WHO, 2021); https://www.who.int/publications/i/item/9789240030060
2. WHO Expert Advisory Committee on Developing Global Standards for Governance and Oversight of Human Genome Editing. Human Genome Editing: Position Paper (WHO, 2021); https://www.who.int/publications/i/item/9789240030404
3. WHO Expert Advisory Committee on Developing Global Standards for Governance and Oversight of Human Genome Editing. Human Genome Editing: Recommendations (WHO, 2021); https://www.who.int/publications/i/item/9789240030381
4. Alhakamy, N. A., Curiel, D. T. & Berkland, C. J. Drug Disc. Today 26, 1602–1619 (2021).
5. Spark Therapeutics. Spark Therapeutics announces first-of-their-kind programs to improve patient access to Luxturna (voretigene neparvovec-rzyl), a one-time gene therapy treatment. https://sparktx.com/press_releases/spark-therapeutics-announces-first-of-their-kind-programs-to-improve-patient-access-to-luxturna-voretigene-neparvovec-rzyl-a-one-time-gene-therapy-treatment/ (2018).